Sequential implementation of stepwise procedures for identifying the maximum tolerated dose

Journal of the American Statistical Association

Volumn 102, Issue 480, 2007, Pages 1448-1461

  Cheung, Ying Kuen ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Algorithm based design; Background toxicity; Familywise error rate; Least favorable configuration; Minimum overdose; Phase I trial; Unbiased selection

Indexed keywords

EID: 38349062295     PISSN: 01621459     EISSN: None     Source Type: Journal    
DOI: 10.1198/016214507000000699     Document Type: Article

References (20)

1. Cheung, Y. K. (2005), "Coherence Principles in Dose-Finding Studies," Biometrika, 92, 863-873.
2. Durham, S. D., Flournoy, N., and Rosenberger, W. F. (1997), "A Random-Walk Rule for Phase I Clinical Trials," Biometrics, 53, 745-760.
3. Hoel, D. G. (1970), "On the Monotonicity of the OC of an SPRT," The Annals of Mathematical Statistics, 41, 310-314.
4. Hsu, J. C. (1981), "Simultaneous Confidence Intervals for All Distances From the Best," The Annals of Statistics, 9, 1026-1034.
5. _ (1984), "Constrained Simultaneous Confidence Intervals for Multiple Comparisons With the Best," The Annals of Statistics, 12, 1136-1144.
6. Hsu, J. C., and Berger, R. L. (1999), "Stepwise Confidence Intervals Without Multiplicity Adjustment for Dose-Response and Toxicity Studies," Journal of the American Statistical Association, 94, 468-482.
7. Lehmann, E. L. (1986), Testing Statistical Hypothesis (2nd ed.), New York: Wiley.
8. Lin, Y., and Shih, W. J. (2001), "Statistical Properties of the Traditional Algorithm-Based Designs for Phase I Cancer Trials," Biostatistics, 2, 203-215.
9. Marcus, R., Peritz, E., and Gabriel, K. R. (1976), "Closed Testing Procedures With Special Reference to Ordered Analysis of Variance," Biometrika, 63, 655-660.
10. O'Quigley, J., and Shen, L. Z. (1996), "Continual Reassessment Method: A Likelihood Approach," Biometrics, 52, 673-684.
11. O'Quigley, J., Pepe, M., and Fisher, L. (1990), "Continual Reassessment Method: A Practical Design for Phase I Clinical Trials in Cancer," Biometrics, 46, 33-48.
12. Shen, L. Z., and O'Quigley, J. (1996), "Consistency of Continual Reassessment Method Under Model Misspecification," Biometrika, 83, 395-405.
13. Storer, B. E. (1989), "Design and Analysis of Phase I Clinical Trials," Biometrics, 45, 925-937.
14. Storer, B., and DeMets, D. (1987), "Current Phase I/II Designs: Are They Adequate?" Journal of Clinical Research and Drug Development, 1, 121-130.
15. Stylianou, M., and Flournoy, N. (2002), "Dose Finding Using the Biased Coin Up-and-Down Design and Isotonic Regression," Biometrics, 58, 171-177.
16. Tamhane, A. C., Dunnett, C. W., Green, J. W., and Wetherington, J. D. (2001), "Multiple Test Procedures for Identifying the Maximum Safe Dose," Journal of the American Statistical Association, 96, 835-843.
17. Tamhane, A. C., Hochberg, Y., and Dunnett, C. W. (1996), "Multiple Test Procedures for Dose Finding," Biometrics, 52, 21-37.
18. Teal, P., Silver, F. L., and Simard, D. (2005), "The BRAINS Study: Safety, Tolerability, and Dose-Rinding of Repinotan in Acute Stroke," The Canadian Journal of Neurological Sciences, 32, 61-67.
19. Wald, A. (1945), "Sequential Tests of Statistical Hypotheses," The Annals of Mathematical Statistics, 16, 117-186.
20. Wald, A., and Wolfowitz, J. (1948), "Optimum Character of the Sequential Probability Ratio Test," The Annals of Mathematical Statistics, 19, 326-339.